BioSpace News Archive

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block the CD47 checkpoint mechanism, today announced new results from ASPEN-01, the ALX148 Phase 1b study, evaluating patients with solid tumor malignancies at the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting [abstract 404].

Eureka Therapeutics, Inc. , a clinical stage biotechnology company developing novel T cell therapies to treat solid tumors, announced today that Randy Schekman, Ph.D., has been appointed to its Scientific Advisory Board. Dr. Schekman shared the 2013 Nobel Prize for Physiology or Medicine for his ground-breaking work on cell membrane vesicle trafficking. He is currently a Professor in the Department of Molecular and Ce

Beroni Group, an Australia-based diversified biopharmaceutical enterprise announced that the Company has been recognized as one of the 2020’s infection control solutions companies in Asia Pacific by MedTech Outlook.

Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced a series of recently issued patents for its Phase 2b/3 clinical-stage lead product candidate, Validive (clonidine HCl mucobuccal tablet). These patents, including U.S. Patent No. 10,675,271, provide claims covering

Charles River Laboratories International, Inc. announced that it will virtually present at three upcoming investor conferences, including

Castellum, Inc. (OTC: ONOV) announces filing its third quarter (Q3) operating results for the period ended September 30, 2020

ProTec 99 is the solution for quick and affordable sterilization in a wide variety of areas. This patent-pending product employs proprietary technology in a handheld device that allows the user to scan surfaces while emitting powerful UV-C radiation.

The Cystic Fibrosis Registry Global Harmonization Group, including the CF Foundation, published in the Journal of Cystic Fibrosis updated data on the impact of COVID-19 on people with cystic fibrosis.

Dynatronics Corporation, a leading manufacturer of athletic training, physical therapy, and rehabilitation products, announced the appointment of Norman Roegner III as Chief Financial Officer, effective November 9, 2020.

November 9, 2020 Rafarma Pharmaceuticals, Inc. OTC: shares the following letter to shareholders from Chairman Ilya Shpurov